Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

ABSTRACT:

Objective

To evaluate the cost-effectiveness of first-line treatments for hypertension.

Background

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) found that first-line treatment with lisinopril or amlodipine was not significantly superior to chlorthalidone in terms of the primary endpoint, so differences in costs may be critical for optimizing decision-making.

Methods

Cost-effectiveness analysis was performed using bootstrap resampling to evaluate uncertainty.

Results

Over a patient's lifetime, chlorthalidone was always least expensive (mean $4,802 less than amlodipine, $3,700 less than lisinopril). Amlodipine provided more life-years (LYs) than chlorthalidone in 84% of bootstrap samples (mean 37 days) at an incremental

SUBMITTER: Heidenreich PA 

PROVIDER: S-EPMC2324142 | biostudies-literature | 2008 May

REPOSITORIES: biostudies-literature